 Connection
Vivian Shi to Eczema
This is a "connection" page, showing publications Vivian Shi has written about Eczema.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
8.533 |
|
|
|
-
De DR, Shih T, Hsiao JL, Shi VY. Readability, Quality, and Comprehensiveness of Patient Online Health Resources for Hand Dermatitis. Dermatitis. 2022 May-Jun 01; 33(3):e31-e33.
Score: 0.822
-
Rick JW, Morgan A, De DR, Hsiao JL, Shi VY. Allergens and marketing claims of the most popular baby moisturizers: A product analysis. J Am Acad Dermatol. 2023 01; 88(1):205-207.
Score: 0.821
-
Shi VY, Bhutani T, Fonacier L, Deleuran M, Shumack S, Valdez H, Zhang F, Chan GL, Cameron MC, Yin NC. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022 08; 87(2):351-358.
Score: 0.819
-
Rick JW, Alavi A, Hsiao JL, Yosipovitch G, Shi VY. Atopic dermatitis and hidradenitis suppurativa: An under-recognized pair. J Am Acad Dermatol. 2021 12; 85(6):e387-e388.
Score: 0.775
-
Thompson AM, Chan A, Torabi M, Kromenacker B, Price KN, Hsiao JL, Shi VY. Eczema moisturizers: Allergenic potential, marketing claims, and costs. Dermatol Ther. 2020 11; 33(6):e14228.
Score: 0.734
-
Ludwig CM, Krase JM, Price KN, Lio PA, Shi VY. A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis. J Dermatolog Treat. 2021 Aug; 32(5):503-506.
Score: 0.694
-
Mata E, Loh TY, Ludwig C, Price KN, Fernandez JM, Krase JM, Shi VY. Pharmacy costs of systemic and topical medications for atopic dermatitis. J Dermatolog Treat. 2021 Aug; 32(5):514-516.
Score: 0.693
-
Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019 05; 32(3):e12840.
Score: 0.658
-
Vaughn AR, Sivamani RK, Lio PA, Shi VY. Paternal vs. Maternal Factors in Childhood Atopic Dermatitis. Dermatitis. 2017 Jul-Aug; 28(4):241-245.
Score: 0.588
-
Vaughn AR, Tannhauser P, Sivamani RK, Shi VY. Mother Nature in Eczema: Maternal Factors Influencing Atopic Dermatitis. Pediatr Dermatol. 2017 May; 34(3):240-246.
Score: 0.581
-
Shi VY, Nanda S, Lee K, Armstrong AW, Lio PA. Improving patient education with an eczema action plan: a randomized controlled trial. JAMA Dermatol. 2013 Apr; 149(4):481-3.
Score: 0.438
-
Worm M, Thyssen JP, Schliemann S, Bauer A, Shi VY, Ehst B, Tillmann S, Korn S, Resen K, Agner T. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial. Br J Dermatol. 2022 07; 187(1):42-51.
Score: 0.205
-
Chandan N, Rajkumar JR, Shi VY, Lio PA. A new era of moisturizers. J Cosmet Dermatol. 2021 Aug; 20(8):2425-2430.
Score: 0.192
-
Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. J Dermatolog Treat. 2021 Feb; 32(1):19-28.
Score: 0.173
-
Yang EJ, Hendricks AJ, Beck KM, Shi VY. Bioactive: A new era of bioactive ingredients in topical formulations for inflammatory dermatoses. Dermatol Ther. 2019 11; 32(6):e13101.
Score: 0.172
-
Maarouf M, Hendricks AJ, Shi VY. Bathing Additives for Atopic Dermatitis - A Systematic Review. Dermatitis. 2019 May/Jun; 30(3):191-197.
Score: 0.167
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|